Microbiome

#Drug delivery #Drug development #Drug discovery #Drug repurposing #Microbiome #Mucoadhesive drug delivery #Pharmaceutical industry #Synthetic biology

New podcast: Outside the box thinking for drug discovery success

This is the latest episode of the free DDW narrated podcast, “Outside the box thinking for drug discovery success”, which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Stanford researchers construct the most complete synthetic microbiome, … Read More

#News

#Antibody-based therapeutics #Artificial intelligence (AI) #CAR-T #Mergers and acquisitions #Microbiome #Partnership #Proteomics

Drug discovery deals highlight key growth areas

The latest acquisitions and strategic partnerships in the drug discovery and development sector reveal the areas where companies predict significant growth in the near future: proteomics, CAR-T, antibody discovery, artificial intelligence (AI) and microbiomics. Thermo Fisher Scientific acquires proteomics experts Olink Thermo Fisher Scientific will acquire proteomics company Olink in… Read More

#Business & Investment #News

Women gut microbiome
#Diagnostics #Drug development #Gut microbiome #Microbiome

Microscopic innovations in women’s health 

By Katie Gillette, Senior Project Leader, Eliza French, Analyst, Graham Friedman, Analyst, and Olivia Qiu, Associate, DeciBio.  Earlier this year, we explored the microbiome and its role in drug development across various therapeutic areas. This article will focus on one such area of great unmet need and promise: women's health. Read More

#Exclusive Content

The microbiome
#Drug discovery #Gut microbiome #Microbiome #Precision medicine

The microbiome in precision medicine

Listen to this article on the DDW Podcast: An industry overview of the role of the microbiome in precision medicine, and its interplay with research tools, diagnostics, and therapeutic development. By Katie Gillette, Senior Project Leader, Eliza French, Analyst, and Graham Friedman, Analyst, DeciBio. The human microbiome refers to the vast… Read More

#Exclusive Content #Trends & Analysis

#Allergy #Alzheimer's #Antibodies #Artificial intelligence (AI) #Autism #Cancer drug targets #Cancer research #Drug development #Influenza #Microbiome #Monoclonal antibodies

New DDW Highlights episode live now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week we have heard about a number of studies that demonstrate an inventive… Read More

#News

#Allergy #Alzheimer's #Antibodies #Artificial intelligence (AI) #Autism #Cancer drug targets #Cancer research #Drug development #Influenza #Microbiome #Monoclonal antibodies

This week in drug discovery (26-30 June)  

News round-up for 26-30 June by DDW Digital Content Editor Diana Spencer. This week we have heard about a number of studies that demonstrate an inventive solution to an old problem, either through the use of an original approach or new, advanced technology. Whether… Read More

#News

Gut microbiome
#Autism #Computational chemistry #Gut microbiome #Microbiome

Study proves connection between autism and the microbiome

A new study has revealed consistent biological signals in the human microbiome and other physiological signals associated with autism. The research highlights the need for long-term studies to determine autism’s underlying causes. Taking a new computational approach to the problem, a study published in… Read More

#Editor's Choice #News

Lightbulb, ideas, innovation
#AI #Animal models #Animal testing #BioInnovation Institute #Data science #Drug discovery #Drug research #Microbiome #Regulatory

New podcast: Innovate to reinvent the future of drug discovery

This is the latest episode of the free DDW narrated podcast, “Innovating now to reinvent the future of drug discovery”. It covers three articles written for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “Predictive biomarkers in the… Read More

#News

Microbiome
#Bioinformatics #Gut microbiome #Mergers and acquisitions #Metabolomics #Microbiome

Acquisition will “integrate microbiome and metabolome data”

Microbiome research company Clinical Microbiomics has acquired MS-Omics, a leading provider based in Denmark.   With this acquisition, Clinical Microbiomics hopes to further advance its systems biology platform and help researchers worldwide understand the microbiome and how to impact health and disease.    Anders Grøn, CEO at Clinical Microbiomics, commented: “There is… Read More

#Business & Investment #News

#Drug discovery #Microbiome #Synthetic biology

Stanford researchers construct the most complete synthetic microbiome

Listen to this article on the DDW Podcast: Rebecca McClellan, Scientific Program Manager, Research, Development & Communications, explains how scientists are learning more about the connections between the microbiome and human health to potentially develop first-in-class microbiome therapies. Key studies in the last decade have shown that the gut microbiome, the… Read More

#Exclusive Content

#AI #Data science #Microbiome

Exploiting the microbiome to drive nature – inspired innovation

Listen to this article on the DDW Podcast: Exploitation of microbiome science will unlock multiple commercial opportunities across a number of industries including life sciences. But there is a need for more effective data and process management to get the best from microbiome data, according to Dr Sven Sewitz, Director of… Read More

#Exclusive Content

Bacteria
#Drug development #Drug discovery #Events #Microbiome #Therapeutics

Take aways from Microba’s presentation at European summit

Microba Life Sciences, a precision microbiome science company based in Australia, showcased its therapeutic platform and discovery platform for the identification of novel microbial signatures at Microbiome Movement, a European drug development summit, on January 27.  The event  The event brought together researchers from the biopharmaceutical… Read More

#News

#Infectious diseases #Microbiome

Microba Life Sciences receive landmark accreditation for Australia 

Microba technology has been used for microbiome analysis to unlock diagnostic applications. This has led to the company receiving ISO15189 accreditation for a new untargeted NGS based assay of stool samples. This makes the company the first Australian microbiome company granted ISO15189 accreditation by NATA (The National Association of Testing… Read More

#News

#Biotechnology #Microbiome #Neuroscience

Gut-brain research could result in improved cognitive performance 

In a collaborative project funded by the Next Generation Technologies Fund, researchers from the University of Newcastle and Queensland University of Technology in Australia will investigate the human, microbial and environmental interactions that affect cognitive performance, coined the ‘cognobiome’, by analysing the gut microbiome of soldiers.  The study … Read More

#News

Stomach pain
#Clinical trials #Irritable Bowel Syndrome #Microbiome

4D Pharma presents microbiome analyses from IBS Phase II clinical trial 

4D Pharma, a pharmaceutical company developing Live Biotherapeutic products (LBPs), has announced new faecal microbiome analyses from the completed Phase II trial of Blautix(R) (MRx1234) as a treatment for irritable bowel syndrome with constipation (IBS-C) or with diarrhoea (IBS-D). The new data was presented in an ePoster at Gastro 2021, held from December 9-11, 2021. … Read More

#News

#Biotechnology #Drug development #Immunology / Virology & Vaccines #Microbiome #R&D

Sanofi acquisition is move for acne vaccine candidate 

Sanofi will acquire Origimm Biotechnology in December 2021, an Austrian biotechnology company specialising in the discovery of virulent skin microbiome components and antigens from bacteria-causing skin disease (such as acne), adding ORI-001 to Sanofi’s early-stage pipeline.  What is ORI-001?  ORI-001 is a therapeutic vaccine candidate for acne vulgaris based… Read More

#News